{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:33:48Z","timestamp":1792272828210,"version":"4.4.0"},"reference-count":254,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019091","name":"Key Research and Development Program of Hunan Province of China","doi-asserted-by":"publisher","award":["251111310300"],"award-info":[{"award-number":["251111310300"]}],"id":[{"id":"10.13039\/501100019091","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009101","name":"Education Department of Henan Province","doi-asserted-by":"publisher","award":["22ZX008"],"award-info":[{"award-number":["22ZX008"]}],"id":[{"id":"10.13039\/501100009101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82020108030"],"award-info":[{"award-number":["82020108030"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204213"],"award-info":[{"award-number":["82204213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U21A20416"],"award-info":[{"award-number":["U21A20416"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020790","name":"Hunan Association for Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020790","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006407","name":"Henan Province Natural Science Foundation","doi-asserted-by":"publisher","award":["252300421127"],"award-info":[{"award-number":["252300421127"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.bmc.2025.118497","type":"journal-article","created":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T22:49:55Z","timestamp":1763938195000},"page":"118497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Unveiling the power of quinazoline derivatives: a new frontier in targeted cancer therapy"],"prefix":"10.1016","volume":"133","author":[{"given":"Hao-Zhe","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Jie","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Qian","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong-Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Jie","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2025","key":"10.1016\/j.bmc.2025.118497_bb0005","first-page":"10","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bmc.2025.118497_bb0010","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bmc.2025.118497_bb0015","article-title":"In response to precision medicine: current subcellular targeting strategies for Cancer therapy","volume":"35","author":"Li","year":"2023","journal-title":"Adv Mater"},{"key":"10.1016\/j.bmc.2025.118497_bb0020","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154943","article-title":"Targeting mutations in cancer","volume":"132","author":"Waarts","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bmc.2025.118497_bb0025","doi-asserted-by":"crossref","first-page":"189250","DOI":"10.1016\/j.bbcan.2024.189250","article-title":"Precision oncology: using cancer genomics for targeted therapy advancements","volume":"1880","author":"Avci","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.bmc.2025.118497_bb0030","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/tcr.201800024","article-title":"Recent advances and developments of in vitro evaluation of heterocyclic moieties on Cancer cell lines","volume":"19","author":"Tandon","year":"2019","journal-title":"Chem Rec"},{"key":"10.1016\/j.bmc.2025.118497_bb0035","doi-asserted-by":"crossref","first-page":"11622","DOI":"10.1021\/acs.jmedchem.4c01122","article-title":"An update on the nitrogen heterocycle compositions and properties of U.S. FDA-approved pharmaceuticals (2013\u22122023)","volume":"67","author":"Marshall","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0040","doi-asserted-by":"crossref","first-page":"113016","DOI":"10.1016\/j.ejmech.2020.113016","article-title":"Therapeutic progression of quinazolines as targeted chemotherapeutic agents","volume":"211","author":"Bansal","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0045","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ejmech.2018.03.076","article-title":"An overview of quinazolines: pharmacological significance and recent developments","volume":"151","author":"Alagarsamy","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0050","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2025.118497_bb0055","doi-asserted-by":"crossref","first-page":"11924","DOI":"10.1158\/0008-5472.CAN-07-1885","article-title":"PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib","volume":"67","author":"Engelman","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2025.118497_bb0060","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1158\/1535-7163.MCT-11-0730","article-title":"Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib","volume":"11","author":"Kalous","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2025.118497_bb0065","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","article-title":"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.bmc.2025.118497_bb0070","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2025.118497_bb0075","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-lung 2, LUX-lung 3, and LUX-lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bmc.2025.118497_bb0080","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.bcp.2012.04.010","article-title":"Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance","volume":"84","author":"Hegedus","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmc.2025.118497_bb0085","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-11-2041","article-title":"Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice","volume":"18","author":"Inoue","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2025.118497_bb0090","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2025.118497_bb0095","first-page":"85","article-title":"The effects of the novel, reversible epidermal growth factor receptor\/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo","volume":"1","author":"Rusnak","year":"2001","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2025.118497_bb0100","first-page":"4838","article-title":"Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase","volume":"57","author":"Moyer","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2025.118497_bb0105","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1158\/1535-7163.MCT-08-0354","article-title":"Apoptosis-inducing effect of erlotinib is potentiated by 3,3\u2032-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer","volume":"7","author":"Ali","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2025.118497_bb0110","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bmc.2025.118497_bb0115","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/sj.bjc.6602793","article-title":"Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII","volume":"93","author":"Pedersen","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bmc.2025.118497_bb0120","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/aps.2017.124","article-title":"Gefitinib inhibits M2-like polarization of tumor-associated macrophages in Lewis lung cancer by targeting the STAT6 signaling pathway","volume":"38","author":"Tariq","year":"2017","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.bmc.2025.118497_bb0125","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1371\/journal.pmed.0040316","article-title":"Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics","volume":"4","author":"Cragg","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.bmc.2025.118497_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118762","article-title":"Effects of gefitinib treatment on cellular uptake of extracellular vesicles in EGFR-mutant non-small cell lung cancer cells","volume":"572","author":"Takenaka","year":"2019","journal-title":"Int J Pharm"},{"key":"10.1016\/j.bmc.2025.118497_bb0135","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2025.118497_bb0140","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","article-title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study","volume":"402","author":"Dasari","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2025.118497_bb0145","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1158\/1078-0432.CCR-16-1496","article-title":"Phase I study of ONT-380, a HER2 inhibitor, in patients with HER2(+)-advanced solid tumors, with an expansion cohort in HER2(+) metastatic breast Cancer (MBC)","volume":"23","author":"Moulder","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2025.118497_bb0150","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1158\/1538-7445.AM2012-852","article-title":"Abstract 852: ARRY-380, a potent, small molecule inhibitor of ErbB2, increases survival in intracranial ErbB2+ xenograft models in mice","volume":"72","author":"Dinkel","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2025.118497_bb0155","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1158\/0008-5472.SABCS-09-5104","article-title":"In vivo activity of ARRY-380, a potent, small molecule inhibitor of ErbB2 in combination with Trastuzumab, docetaxel or bevacizumab","volume":"69","author":"Lee","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2025.118497_bb0160","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1146\/annurev-biochem-060614-034402","article-title":"A structural perspective on the regulation of the epidermal growth factor receptor","volume":"84","author":"Kovacs","year":"2015","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.bmc.2025.118497_bb0165","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semcancer.2022.04.002","article-title":"EGFR signaling pathway as therapeutic target in human cancers","volume":"85","author":"Levantini","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.bmc.2025.118497_bb0170","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.2147\/DDDT.S119162","article-title":"Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer","volume":"10","author":"Zhang","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.bmc.2025.118497_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188967","article-title":"20 years since the approval of first EGFR-TKI, gefitinib: insight and foresight","volume":"1878","author":"Singh","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.bmc.2025.118497_bb0180","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.drup.2011.02.004","article-title":"Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review","volume":"14","author":"Murphy","year":"2011","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.bmc.2025.118497_bb0185","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(13)70355-3","article-title":"Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial","volume":"14","author":"Shi","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bmc.2025.118497_bb0190","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12943-018-0777-1","article-title":"Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer","volume":"17","author":"Wu","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.bmc.2025.118497_bb0195","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1016\/S1470-2045(13)70402-9","article-title":"Afatinib in NSCLC harbouring EGFR mutations","volume":"15","author":"de Marinis","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bmc.2025.118497_bb0200","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bmc.2025.118497_bb0205","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jtho.2019.12.126","article-title":"Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases","volume":"15","author":"Yang","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.bmc.2025.118497_bb0210","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2025.118497_bb0215","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","article-title":"Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance","volume":"15","author":"Fu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bmc.2025.118497_bb0220","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/JTO.0000000000000095","article-title":"Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21","volume":"9","author":"Lim","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.bmc.2025.118497_bb0225","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2025.118497_bb0230","doi-asserted-by":"crossref","first-page":"106057","DOI":"10.1016\/j.bioorg.2022.106057","article-title":"Overcoming C797S mutation: the challenges and prospects of the fourth-generation EGFR-TKIs","volume":"128","author":"Zhao","year":"2022","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0235","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1093\/annonc\/mdx359","article-title":"First-line icotinib versus cisplatin\/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study","volume":"28","author":"Shi","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bmc.2025.118497_bb0240","doi-asserted-by":"crossref","first-page":"8200","DOI":"10.1021\/acs.jmedchem.5b01073","article-title":"Discovery and evaluation of clinical candidate AZD3759, a potent, Oral active, central nervous system-penetrant, epidermal growth factor receptor tyrosine kinase inhibitor","volume":"58","author":"Zeng","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0245","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ccell.2022.06.006","article-title":"Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity","volume":"40","author":"Elamin","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bmc.2025.118497_bb0250","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1158\/1078-0432.CCR-09-2353","article-title":"AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer","volume":"16","author":"Hickinson","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2025.118497_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114856","article-title":"Discovery and optimization of 4-anilinoquinazoline derivatives spanning ATP binding site and allosteric site as effective EGFR-C797S inhibitors","volume":"244","author":"Dou","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0260","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1021\/acsmedchemlett.8b00564","article-title":"Discovery of potent and noncovalent reversible EGFR kinase inhibitors of EGFR(L858R\/T790M\/C797S)","volume":"10","author":"Li","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118497_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117137","article-title":"Gold(I) complexes bearing EGFR-inhibiting ligands as anti-HCC agents through dual targeting of EGFR and TrxR","volume":"283","author":"Wang","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108991","article-title":"Quinazoline-based fourth-generation EGFR tyrosine kinase inhibitors to overcome C797S-mediated resistance in non-small cell lung Cancer (NSCLC)","volume":"165","author":"Patil","year":"2025","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117502","article-title":"6,7-Dimethoxy-2-methyl-4-substituted quinazolines: design, synthesis, EGFR inhibitory activity, in vitro cytotoxicity, and in silico studies","volume":"290","author":"Saleh","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116858","article-title":"Design, synthesis, and biological evaluation of diphenyl ether substituted quinazolin-4-amine derivatives as potent EGFR(L858R\/T790M\/C797S) inhibitors","volume":"279","author":"Dou","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0285","doi-asserted-by":"crossref","first-page":"106970","DOI":"10.1016\/j.bioorg.2023.106970","article-title":"Design, synthesis and biological evaluation of structurally new 4-indolyl quinazoline derivatives as highly potent, selective and orally bioavailable EGFR inhibitors","volume":"142","author":"He","year":"2024","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106510","article-title":"Antitumor activity and mechanisms of dual EGFR\/DNA-targeting strategy for the treatment of lung cancer with EGFR(L858R\/T790M) mutation","volume":"135","author":"Dai","year":"2023","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0295","doi-asserted-by":"crossref","first-page":"599281","DOI":"10.3389\/fcell.2020.599281","article-title":"Molecular bases of VEGFR-2-mediated physiological function and pathological role","volume":"8","author":"Wang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.bmc.2025.118497_bb0300","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s10456-024-09942-8","article-title":"Soluble FLT-1 in angiogenesis: pathophysiological roles and therapeutic implications","volume":"27","author":"Wazan","year":"2024","journal-title":"Angiogenesis"},{"key":"10.1016\/j.bmc.2025.118497_bb0305","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13045-022-01310-7","article-title":"Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy","volume":"15","author":"Liu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bmc.2025.118497_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115626","article-title":"Quinazoline-based VEGFR-2 inhibitors as potential anti-angiogenic agents: a contemporary perspective of SAR and molecular docking studies","volume":"259","author":"Moradi","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0315","doi-asserted-by":"crossref","first-page":"100043","DOI":"10.1016\/j.esmoop.2020.100043","article-title":"Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial","volume":"6","author":"Ledermann","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.bmc.2025.118497_bb0320","doi-asserted-by":"crossref","first-page":"103961","DOI":"10.1016\/j.bioorg.2020.103961","article-title":"Scaffold hopping and redesign approaches for quinazoline based urea derivatives as potent VEGFR-2 inhibitors","volume":"101","author":"Hadi","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0325","article-title":"Design, synthesis, anticancer evaluation, biological screening, and computational study of novel 6,7-dimethoxyquinazoline derivatives as VEGFR-2 inhibitors and apoptotic inducers","volume":"301","author":"Aref","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0330","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41421-023-00523-5","article-title":"Structure and dynamics of the EGFR\/HER2 heterodimer","volume":"9","author":"Bai","year":"2023","journal-title":"Cell Discov"},{"issue":"suppl 1","key":"10.1016\/j.bmc.2025.118497_bb0335","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/annonc\/12.suppl_1.S3","article-title":"The basic biology of HER2","volume":"12","author":"Rubin","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bmc.2025.118497_bb0340","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2025.118497_bb0345","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ctrv.2013.01.006","article-title":"A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer","volume":"39","author":"Larsen","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bmc.2025.118497_bb0350","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/jnci\/djad072","article-title":"Tucatinib promotes immune activation and synergizes with programmed cell death-1 and programmed cell death-ligand 1 inhibition in HER2-positive breast cancer","volume":"115","author":"Li","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bmc.2025.118497_bb0355","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3390\/cancers11010105","article-title":"Varlitinib downregulates HER\/ERK signaling and induces apoptosis in triple negative breast Cancer cells","volume":"11","author":"Liu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmc.2025.118497_bb0360","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1158\/1535-7163.MCT-20-0640","article-title":"In vivo efficacy of Tesevatinib in EGFR-amplified patient-derived xenograft glioblastoma models may be limited by tissue binding and compensatory signaling","volume":"20","author":"Kizilbash","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2025.118497_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107686","article-title":"Design, synthesis and biological evaluation of novel quinazoline-derived EGFR\/HER-2 dual-target inhibitors bearing a heterocyclic-containing tail as potential anti-tumor agents","volume":"151","author":"Hao","year":"2024","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0370","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2015.01.003","article-title":"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors","volume":"94","author":"Roskoski","year":"2015","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bmc.2025.118497_bb0375","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1023\/A:1023772912750","article-title":"Src family kinases in tumor progression and metastasis","volume":"22","author":"Summy","year":"2003","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.bmc.2025.118497_bb0380","doi-asserted-by":"crossref","first-page":"117369","DOI":"10.1016\/j.ejmech.2025.117369","article-title":"Advancing Src kinase inhibition: from structural design to therapeutic innovation - a comprehensive review","volume":"287","author":"Su","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0385","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1164\/rccm.202010-3832OC","article-title":"Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis","volume":"206","author":"Ahangari","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.bmc.2025.118497_bb0390","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1038\/bjc.2012.158","article-title":"Phase I study of saracatinib (AZD0530) in combination with paclitaxel and\/or carboplatin in patients with solid tumours","volume":"106","author":"Kaye","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bmc.2025.118497_bb0395","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/1878-0261.13151","article-title":"Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors for cancer treatment","volume":"16","author":"Dawson","year":"2022","journal-title":"Mol Oncol"},{"key":"10.1016\/j.bmc.2025.118497_bb0400","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1111\/bph.13623","article-title":"Smooth muscle contraction and growth of stromal cells in the human prostate are both inhibited by the Src family kinase inhibitors, AZM475271 and PP2","volume":"173","author":"Wang","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmc.2025.118497_bb0405","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1023\/A:1023768811842","article-title":"C-met: structure, functions and potential for therapeutic inhibition","volume":"22","author":"Ma","year":"2003","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.bmc.2025.118497_bb0410","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/JTO.0b013e3182417e44","article-title":"MET signaling: novel targeted inhibition and its clinical development in lung cancer","volume":"7","author":"Feng","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.bmc.2025.118497_bb0415","first-page":"S21","article-title":"C-MET as a potential therapeutic target and biomarker in cancer, therapeutic advances in medical","volume":"3","author":"Sierra","year":"2011","journal-title":"Oncology"},{"key":"10.1016\/j.bmc.2025.118497_bb0420","doi-asserted-by":"crossref","first-page":"2189578","DOI":"10.1080\/14756366.2023.2189578","article-title":"Design and biological evaluation of 3-substituted quinazoline-2,4(1 H, 3 H)-dione derivatives as dual c-Met\/VEGFR-2-TK inhibitors","volume":"38","author":"Hassan","year":"2023","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106938","article-title":"Novel quinazoline-based dual EGFR\/c-met inhibitors overcoming drug resistance for the treatment of NSCLC: design, synthesis and anti-tumor activity","volume":"142","author":"Zhang","year":"2024","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0430","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/cells8060614","article-title":"Fibroblast growth factor receptors (FGFRs): structures and small molecule inhibitors","volume":"8","author":"Dai","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.bmc.2025.118497_bb0435","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s10495-013-0886-7","article-title":"Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers","volume":"18","author":"Tiong","year":"2013","journal-title":"Apoptosis"},{"key":"10.1016\/j.bmc.2025.118497_bb0440","doi-asserted-by":"crossref","first-page":"490","DOI":"10.20892\/j.issn.2095-3941.2023.0137","article-title":"Current progress in cancer treatment by targeting FGFR signaling","volume":"20","author":"Du","year":"2023","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.bmc.2025.118497_bb0445","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","article-title":"First-in-human phase I study of Fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma","volume":"9","author":"Kim","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bmc.2025.118497_bb0450","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.3390\/cancers12102976","article-title":"FGFR4 inhibitor BLU9931 attenuates pancreatic Cancer cell proliferation and invasion while inducing senescence: evidence for Senolytic therapy potential in pancreatic Cancer","volume":"12","author":"Sasaki","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bmc.2025.118497_bb0455","first-page":"424","article-title":"First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway, Cancer","volume":"5","author":"Hagel","year":"2015","journal-title":"Discovery"},{"key":"10.1016\/j.bmc.2025.118497_bb0460","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3892\/ijo.2017.4143","article-title":"Combination of FGFR4 inhibitor Blu9931 and 5-fluorouracil effects on the biological characteristics of colorectal cancer cells","volume":"51","author":"Jiang","year":"2017","journal-title":"Int J Oncol"},{"key":"10.1016\/j.bmc.2025.118497_bb0465","doi-asserted-by":"crossref","first-page":"113794","DOI":"10.1016\/j.ejmech.2021.113794","article-title":"Design, synthesis and biological evaluation of quinazoline derivatives as potent and selective FGFR4 inhibitors","volume":"225","author":"Pan","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0470","doi-asserted-by":"crossref","first-page":"11307","DOI":"10.1073\/pnas.1000806107","article-title":"Structures of a platelet-derived growth factor\/propeptide complex and a platelet-derived growth factor\/receptor complex","volume":"107","author":"Shim","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmc.2025.118497_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103989","article-title":"Current status of drugs targeting PDGF\/PDGFR","volume":"29","author":"Ai","year":"2024","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bmc.2025.118497_bb0480","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s10555-024-10194-7","article-title":"Functional and clinical roles of stromal PDGF receptors in tumor biology","volume":"43","author":"Strell","year":"2024","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.bmc.2025.118497_bb0485","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S1470-2045(20)30269-2","article-title":"Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial","volume":"21","author":"Heinrich","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bmc.2025.118497_bb0490","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/onco.13901","article-title":"Neoadjuvant treatment with angiogenesis-inhibitor Dovitinib Prior to local therapy in hepatocellular carcinoma: a phase II study","volume":"26","author":"Woei","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.bmc.2025.118497_bb0495","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s10637-010-9516-1","article-title":"A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma","volume":"30","author":"Shepard","year":"2012","journal-title":"Investig New Drugs"},{"key":"10.1016\/j.bmc.2025.118497_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118015","article-title":"Design, synthesis and biological evaluation of novel platelet-derived growth factor receptor-alpha (PDGFR-alpha) inhibitors based on 4-anilinoquinoline and 4-anilinoquinazoline scaffolds","volume":"298","author":"Wang","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0505","first-page":"402","article-title":"The JAK\/STAT signaling pathway: from bench to clinic, signal transduction and targeted","volume":"6","author":"Hu","year":"2021","journal-title":"Therapy"},{"key":"10.1016\/j.bmc.2025.118497_bb0510","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41392-024-01934-w","article-title":"The JAK-STAT pathway: from structural biology to cytokine engineering","volume":"9","author":"Lv","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmc.2025.118497_bb0515","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1038\/s41375-025-02594-7","article-title":"Ruxolitinib mediated paradoxical JAK2 hyperphosphorylation is due to the protection of activation loop tyrosines from phosphatases","volume":"39","author":"Gorantla","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.bmc.2025.118497_bb0520","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40364-019-0166-y","article-title":"Targeted therapies for myeloproliferative neoplasms","volume":"7","author":"Li","year":"2019","journal-title":"Biomark Res"},{"key":"10.1016\/j.bmc.2025.118497_bb0525","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.3390\/cancers13205204","article-title":"Second-generation Jak2 inhibitors for advanced prostate Cancer: are we ready for clinical development?","volume":"13","author":"Beinhoff","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmc.2025.118497_bb0530","doi-asserted-by":"crossref","first-page":"viii5","DOI":"10.1093\/annonc\/mdz383","article-title":"Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer","volume":"30","author":"Amatu","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bmc.2025.118497_bb0535","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1146\/annurev.biochem.72.121801.161629","article-title":"Trk receptors: roles in neuronal signal transduction","volume":"72","author":"Huang","year":"2003","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.bmc.2025.118497_bb0540","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.pharmthera.2017.02.006","article-title":"Targeting TRK family proteins in cancer","volume":"173","author":"Khotskaya","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmc.2025.118497_bb0545","first-page":"731","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy, nature reviews","volume":"15","author":"Cocco","year":"2018","journal-title":"Clin Oncol"},{"key":"10.1016\/j.bmc.2025.118497_bb0550","doi-asserted-by":"crossref","first-page":"114451","DOI":"10.1016\/j.ejmech.2022.114451","article-title":"Discovery of quinazoline derivatives CZw-124 as a pan-TRK inhibitor with potent anticancer effects in vitro and in vivo","volume":"238","author":"Wu","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0555","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.1038\/ncomms7769","article-title":"CDK1 structures reveal conserved and unique features of the essential cell cycle CDK","volume":"6","author":"Brown","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2025.118497_bb0560","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/374131a0","article-title":"Principles of CDK regulation","volume":"374","author":"Morgan","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2025.118497_bb0565","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ijbiomac.2022.07.156","article-title":"Structure-guided design and development of cyclin-dependent kinase 4\/6 inhibitors: a review on therapeutic implications","volume":"218","author":"Yousuf","year":"2022","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.bmc.2025.118497_bb0570","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/gb4184","article-title":"Cyclin-dependent kinases","volume":"15","author":"Malumbres","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.bmc.2025.118497_bb0575","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s12276-025-01395-3","article-title":"Targeting CDK4\/6 in breast cancer","volume":"57","author":"Shanabag","year":"2025","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.bmc.2025.118497_bb0580","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1016\/j.bmcl.2005.05.131","article-title":"2-Aminoquinazoline inhibitors of cyclin-dependent kinases","volume":"15","author":"Bathini","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118497_bb0585","first-page":"153","article-title":"Design, synthesis, molecular docking, and evaluation of sulfonyl quinazoline analogues as promising liver cancer drugs","author":"Venkatesan","year":"2024","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0590","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.2014.59.0018","article-title":"Inhibition of the PI3K\/AKT\/mTOR pathway in solid tumors","volume":"34","author":"LoRusso","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2025.118497_bb0595","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.bmc.2025.118497_bb0600","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-024-02072-1","article-title":"Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions","volume":"23","author":"Li","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.bmc.2025.118497_bb0605","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1021\/jm200386s","article-title":"Phospshoinositide 3-Kinase (PI3K)\/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Discovery and Structure\u2013Activity Relationships of a Series of Quinoline and Quinoxaline Derivatives","volume":"54","author":"Nishimura","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0610","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41419-020-2690-y","article-title":"A novel 4-aminoquinazoline derivative, DHW-208, suppresses the growth of human breast cancer cells by targeting the PI3K\/AKT\/mTOR pathway","volume":"11","author":"Wang","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.bmc.2025.118497_bb0615","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1016\/j.bmcl.2016.08.015","article-title":"Synthesis and antitumor activity evaluation of 4,6-disubstituted quinazoline derivatives as novel PI3K inhibitors","volume":"26","author":"Hei","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118497_bb0620","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ejmech.2015.04.037","article-title":"Synthesis and antitumor activities evaluation of m-(4-morpholinoquinazolin-2-yl)benzamides in vitro and in vivo","volume":"96","author":"Wang","year":"2015","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0625","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ejmech.2015.11.038","article-title":"Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino- N -(pyridin-3-yl)quinazolin-7-amines as novel PI3K\/mTOR inhibitors and anticancer agents","volume":"108","author":"Peng","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0630","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ejmech.2016.07.006","article-title":"6-aryl substituted 4-(4-cyanomethyl) phenylamino quinazolines as a new class of isoform-selective PI3K-alpha inhibitors","volume":"122","author":"Yadav","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0635","doi-asserted-by":"crossref","first-page":"112865","DOI":"10.1016\/j.ejmech.2020.112865","article-title":"Discovery of novel quinazoline derivatives as potent PI3K\u03b4 inhibitors with high selectivity","volume":"208","author":"Teng","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0640","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jare.2024.03.002","article-title":"Hybridization-based discovery of novel quinazoline-2-indolinone derivatives as potent and selective PI3Kalpha inhibitors","volume":"68","author":"Liu","year":"2025","journal-title":"J Adv Res"},{"key":"10.1016\/j.bmc.2025.118497_bb0645","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ctrv.2007.09.005","article-title":"Aurora kinases as targets for cancer therapy","volume":"34","author":"Mountzios","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bmc.2025.118497_bb0650","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1023\/A:1023789416385","article-title":"The Aurora kinases: role in cell transformation and tumorigenesis","volume":"22","author":"Katayama","year":"2003","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.bmc.2025.118497_bb0655","doi-asserted-by":"crossref","first-page":"107976","DOI":"10.1016\/j.bioorg.2024.107976","article-title":"Recent advancements in mechanistic research, therapeutic potential, and structure-activity relationships of aurora kinase inhibitors in cancer therapies","volume":"154","author":"Teli","year":"2025","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0660","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41467-025-56504-7","article-title":"High-throughput screening identifies Aurora kinase B as a critical therapeutic target for Merkel cell carcinoma","volume":"16","author":"Gelb","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2025.118497_bb0665","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejmech.2019.03.004","article-title":"Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry","volume":"170","author":"Das","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0670","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1083\/jcb.200208091","article-title":"Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores","volume":"161","author":"Ditchfield","year":"2003","journal-title":"J Cell Biol"},{"key":"10.1016\/j.bmc.2025.118497_bb0675","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000258705","article-title":"ZM447439, a novel promising aurora kinase inhibitor, provokes antiproliferative and proapoptotic effects alone and in combination with bio- and chemotherapeutic agents in gastroenteropancreatic neuroendocrine tumor cell lines","volume":"91","author":"Georgieva","year":"2010","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.bmc.2025.118497_bb0680","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bcp.2009.08.011","article-title":"Aurora kinase inhibitor ZM447439 induces apoptosis via mitochondrial pathways","volume":"79","author":"Li","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmc.2025.118497_bb0685","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1182\/blood-2011-07-366930","article-title":"Phase 1\/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia","volume":"118","author":"L\u00f6wenberg","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bmc.2025.118497_bb0690","doi-asserted-by":"crossref","first-page":"117735","DOI":"10.1016\/j.ejmech.2025.117735","article-title":"Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective Aurora kinase B inhibitor","volume":"294","author":"Tran","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0695","doi-asserted-by":"crossref","first-page":"18197","DOI":"10.1021\/acs.jmedchem.5c00107","article-title":"Optimization of novel Quinazolines as potent Aurora kinase inhibitors for triple-negative breast Cancer treatment","volume":"68","author":"Long","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0700","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.55122","article-title":"A perspective on HPK1 as a novel immuno-oncology drug target","volume":"9","author":"Sawasdikosol","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.bmc.2025.118497_bb0705","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/ni1416","article-title":"Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell-mediated immune responses","volume":"8","author":"Shui","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.bmc.2025.118497_bb0710","doi-asserted-by":"crossref","first-page":"1449106","DOI":"10.3389\/fimmu.2025.1449106","article-title":"HPK1 kinase inhibitor: a sufficient approach to target HPK1 to modulate T cell activation in cancer immunotherapy compared with degraders","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmc.2025.118497_bb0715","doi-asserted-by":"crossref","first-page":"114819","DOI":"10.1016\/j.ejmech.2022.114819","article-title":"The development of small-molecule inhibitors targeting HPK1","volume":"244","author":"Zhou","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0720","doi-asserted-by":"crossref","first-page":"10439","DOI":"10.1021\/acs.jmedchem.5c00762","article-title":"Structure-guided optimization of 2-Aminoquinazoline hematopoietic progenitor kinase 1 inhibitors for improved Oral bioavailability and synergistic antitumor immunity","volume":"68","author":"Wan","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0725","doi-asserted-by":"crossref","first-page":"115064","DOI":"10.1016\/j.ejmech.2022.115064","article-title":"Development of a series of quinazoline-2,5-diamine derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors","volume":"248","author":"Shi","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0730","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1146\/annurev-immunol-041015-055347","article-title":"Protein kinase C enzymes in the hematopoietic and immune systems","volume":"34","author":"Altman","year":"2016","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bmc.2025.118497_bb0735","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.biotechadv.2012.07.004","article-title":"Protein kinase C (PKC) isozyme-specific substrates and their design","volume":"30","author":"Kang","year":"2012","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.bmc.2025.118497_bb0740","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2025.118497_bb0745","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1200\/JCO.2009.26.1149","article-title":"Enzastaurin in the treatment of recurrent glioblastoma: a promise that did not materialize","volume":"28","author":"Galanis","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2025.118497_bb0750","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1158\/0008-5472.CAN-10-2525","article-title":"Protein kinase C inhibitor Sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas","volume":"71","author":"Naylor","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2025.118497_bb0755","first-page":"117","article-title":"Sotrastaurin attenuates the stemness of gastric cancer cells by targeting PKC\u03b4","author":"Yuan","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bmc.2025.118497_bb0760","doi-asserted-by":"crossref","first-page":"102205","DOI":"10.1016\/j.cbpa.2022.102205","article-title":"Mechanism and inhibition of BRAF kinase","volume":"71","author":"Gunderwala","year":"2022","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.bmc.2025.118497_bb0765","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1084\/jem.20051848","article-title":"The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells","volume":"203","author":"Sumimoto","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.bmc.2025.118497_bb0770","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1478-811X-7-8","article-title":"Regulation of cellular proliferation, differentiation and cell death by activated Raf","volume":"7","author":"Thiel","year":"2009","journal-title":"Cell Com Signal"},{"key":"10.1016\/j.bmc.2025.118497_bb0775","doi-asserted-by":"crossref","first-page":"15003","DOI":"10.1038\/nrdp.2015.3","article-title":"Melanoma","volume":"1","author":"Schadendorf","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.bmc.2025.118497_bb0780","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2025.118497_bb0785","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bmc.2025.118497_bb0790","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1021\/jm2009925","volume":"55","author":"Rowbottom","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0795","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/embr.201337983","article-title":"The I\u03baB kinase complex in NF \u2010\u03baB regulation and beyond","volume":"15","author":"Hinz","year":"2013","journal-title":"EMBO reports"},{"key":"10.1016\/j.bmc.2025.118497_bb0800","doi-asserted-by":"crossref","first-page":"7692","DOI":"10.1038\/s41467-024-52076-0","article-title":"Molecular mechanism of IKK catalytic dimer docking to NF-\u03baB substrates","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2025.118497_bb0805","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3390\/cells7090115","article-title":"Targeting IKK\u03b2 in Cancer: challenges and opportunities for the therapeutic utilisation of IKK\u03b2 inhibitors","volume":"7","author":"Prescott","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.bmc.2025.118497_bb0810","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.semcancer.2018.02.007","article-title":"Targeting I\u03baappaB kinases for cancer therapy","volume":"56","author":"Awasthee","year":"2019","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.bmc.2025.118497_bb0815","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/sj.leu.2404614","article-title":"AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells","volume":"21","author":"Griessinger","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bmc.2025.118497_bb0820","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.drudis.2015.01.007","article-title":"Histone deacetylases: structural determinants of inhibitor selectivity","volume":"20","author":"Micelli","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bmc.2025.118497_bb0825","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12943-019-1127-7","article-title":"Role of HDACs in normal and malignant hematopoiesis","volume":"19","author":"Wang","year":"2020","journal-title":"Mol Cancer"},{"key":"10.1016\/j.bmc.2025.118497_bb0830","doi-asserted-by":"crossref","first-page":"117185","DOI":"10.1016\/j.ejmech.2024.117185","article-title":"Synthetic approaches and clinical applications of representative HDAC inhibitors for cancer therapy: a review","volume":"283","author":"Lv","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0835","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s42003-025-07649-0","article-title":"Binding mechanism and distant regulation of histone deacetylase 8 by PCI-34051","volume":"8","author":"Luo","year":"2025","journal-title":"Communications Biology"},{"key":"10.1016\/j.bmc.2025.118497_bb0840","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1158\/0008-5472.CAN-09-3360","article-title":"CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity","volume":"70","author":"Lai","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2025.118497_bb0845","doi-asserted-by":"crossref","first-page":"116524","DOI":"10.1016\/j.bmc.2021.116524","article-title":"Quinazoline-based hydroxamic acid derivatives as dual histone methylation and deacetylation inhibitors for potential anticancer agents","volume":"53","author":"Zheng","year":"2022","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0850","first-page":"62:6992","article-title":"Design, synthesis, and biological evaluation of 4-methyl quinazoline derivatives as anticancer agents simultaneously targeting phosphoinositide 3-kinases and histone deacetylases","author":"Zhang","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0855","doi-asserted-by":"crossref","first-page":"116015","DOI":"10.1016\/j.ejmech.2023.116015","article-title":"Rational design and optimization of novel 4-methyl quinazoline derivatives as PI3K\/HDAC dual inhibitors with benzamide as zinc binding moiety for the treatment of acute myeloid leukemia","volume":"264","author":"Zhang","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0860","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1038\/s12276-020-00542-2","article-title":"LSD1: more than demethylation of histone lysine residues","volume":"52","author":"Perillo","year":"2020","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.bmc.2025.118497_bb0865","doi-asserted-by":"crossref","first-page":"13956","DOI":"10.1073\/pnas.0606381103","article-title":"Crystal structure of human histone lysine-specific demethylase 1 (LSD1)","volume":"103","author":"Chen","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmc.2025.118497_bb0870","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12929-021-00737-3","article-title":"Roles of lysine-specific demethylase 1 (LSD1) in homeostasis and diseases","volume":"28","author":"Kim","year":"2021","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.bmc.2025.118497_bb0875","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1021\/acs.jmedchem.3c02133","article-title":"Combination therapy and dual-target inhibitors based on LSD1: new emerging tools in Cancer therapy","volume":"67","author":"Shen","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0880","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1021\/acs.jmedchem.0c02176","article-title":"Reversible lysine specific demethylase 1 (LSD1) inhibitors: a promising wrench to impair LSD1","volume":"64","author":"Dai","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0885","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.tips.2025.01.006","article-title":"Leveraging non-enzymatic functions of LSD1 for novel therapeutics","volume":"46","author":"Song","year":"2025","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bmc.2025.118497_bb0890","doi-asserted-by":"crossref","first-page":"113778","DOI":"10.1016\/j.ejmech.2021.113778","article-title":"Discovery of quinazoline derivatives as a novel class of potent and in vivo efficacious LSD1 inhibitors by drug repurposing","volume":"225","author":"Li","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0895","doi-asserted-by":"crossref","first-page":"16165","DOI":"10.1021\/acs.jmedchem.4c00972","article-title":"Discovery of 2-Aryl-4-aminoquinazolin-based LSD1 inhibitors to activate immune response in gastric Cancer","volume":"67","author":"Wang","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0900","doi-asserted-by":"crossref","first-page":"114410","DOI":"10.1016\/j.ejmech.2022.114410","article-title":"Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models","volume":"237","author":"Menna","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0905","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0955-0674(98)80082-3","article-title":"Tubulin and microtubule structure","volume":"10","author":"Downing","year":"1998","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.bmc.2025.118497_bb0910","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0092-8674(86)90318-1","article-title":"Beyond self-assembly: from microtubules to morphogenesis","volume":"45","author":"Kirschner","year":"1986","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2025.118497_bb0915","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108726","article-title":"Microtubule dynamics in cancer metastasis: harnessing the underappreciated potential for therapeutic interventions","volume":"263","author":"Mangaonkar","year":"2024","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmc.2025.118497_bb0920","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41420-023-01713-6","article-title":"A novel microtubule inhibitor promotes tumor ferroptosis by attenuating SLC7A11\/GPX4 signaling","volume":"9","author":"Ning","year":"2023","journal-title":"Cell Death Discovery"},{"key":"10.1016\/j.bmc.2025.118497_bb0925","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103283","article-title":"Cytoskeletal proteins as glioblastoma biomarkers and targets for therapy: a systematic review","volume":"160","author":"Zottel","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.bmc.2025.118497_bb0930","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejmech.2013.06.041","article-title":"N-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines: a novel class of antitumor agents targeting the colchicine site on tubulin","volume":"67","author":"Wang","year":"2013","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0935","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1021\/jm4016526","article-title":"Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site","volume":"57","author":"Wang","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0940","doi-asserted-by":"crossref","first-page":"117000","DOI":"10.1016\/j.ejmech.2024.117000","article-title":"Discovery of novel quinazoline derivatives as tubulin polymerization inhibitors targeting the colchicine binding site with potential anti-colon cancer effects","volume":"280","author":"Zhu","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0945","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1021\/ml5004684","article-title":"Synthesis and structure-activity relationship study of 1-Phenyl-1-(quinazolin-4-yl)ethanols as anticancer agents","volume":"6","author":"Kuroiwa","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118497_bb0950","doi-asserted-by":"crossref","first-page":"117139","DOI":"10.1016\/j.ejmech.2024.117139","article-title":"Design, synthesis, and antitumor evaluation of quinazoline-4-tetrahydroquinoline chemotypes as novel tubulin polymerization inhibitors targeting the colchicine site","volume":"283","author":"Lai","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0955","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115470","article-title":"Discovery of novel N-aryl-2-trifluoromethyl-quinazoline-4-amine derivatives as the inhibitors of tubulin polymerization in leukemia cells","volume":"256","author":"Wu","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb0960","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1242\/dev.141465","article-title":"Setd5 is essential for mammalian development and the co-transcriptional regulation of histone acetylation","volume":"143","author":"Osipovich","year":"2016","journal-title":"Development"},{"key":"10.1016\/j.bmc.2025.118497_bb0965","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1021\/acs.chemrev.8b00008","article-title":"Chemical and biochemical perspectives of protein lysine methylation","volume":"118","author":"Luo","year":"2018","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmc.2025.118497_bb0970","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41389-021-00370-7","article-title":"Emerging role of G9a in cancer stemness and promises as a therapeutic target","volume":"10","author":"Haebe","year":"2021","journal-title":"Oncogenesis"},{"key":"10.1016\/j.bmc.2025.118497_bb0975","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1158\/0008-5472.CAN-05-2481","article-title":"Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state","volume":"66","author":"McGarvey","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2025.118497_bb0980","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.09571","article-title":"Chromatin dynamics and the role of G9a in gene regulation and enhancer silencing during early mouse development","volume":"4","author":"Zylicz","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.bmc.2025.118497_bb0985","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.7150\/thno.23824","article-title":"G9a stimulates CRC growth by inducing p53 Lys373 dimethylation-dependent activation of Plk1","volume":"8","author":"Zhang","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.bmc.2025.118497_bb0990","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.molcel.2007.01.017","article-title":"Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase","volume":"25","author":"Kubicek","year":"2007","journal-title":"Mol Cell"},{"key":"10.1016\/j.bmc.2025.118497_bb0995","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nsmb.1560","article-title":"Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294","volume":"16","author":"Chang","year":"2009","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.bmc.2025.118497_bb1000","doi-asserted-by":"crossref","first-page":"7950","DOI":"10.1021\/jm901543m","article-title":"Discovery of a 2,4-Diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a","volume":"52","author":"Liu","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb1005","doi-asserted-by":"crossref","first-page":"5844","DOI":"10.1021\/jm100478y","article-title":"Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-Diamino-7-aminoalkoxy-quinazolines","volume":"53","author":"Liu","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb1010","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1021\/jm200903z","article-title":"Optimization of cellular activity of G9a inhibitors 7-Aminoalkoxy-quinazolines","volume":"54","author":"Liu","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb1015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118113","article-title":"Discovery of 2-tetrahydroisoquinoline substituted quinazoline derivatives as lysine methyltransferase G9a inhibitors with in vivo antitumor efficacy","volume":"300","author":"Shao","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb1020","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature22345","article-title":"Structure of the human multidrug transporter ABCG2","volume":"546","author":"Taylor","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2025.118497_bb1025","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.addr.2008.07.003","article-title":"Functions of the breast cancer resistance protein (BCRP\/ABCG2) in chemotherapy","volume":"61","author":"Noguchi","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.bmc.2025.118497_bb1030","doi-asserted-by":"crossref","first-page":"125987","DOI":"10.1016\/j.talanta.2024.125987","article-title":"High-throughput BCRP inhibitors screening system based on styrene maleic acid polymer membrane protein stabilization strategy and surface plasmon resonance biosensor","volume":"274","author":"Fang","year":"2024","journal-title":"Talanta"},{"key":"10.1016\/j.bmc.2025.118497_bb1035","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1158\/0008-5472.596.65.2","article-title":"Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein\/ABCG2","volume":"65","author":"Imai","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2025.118497_bb1040","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1158\/0008-5472.CAN-03-2417","article-title":"Gefitinib (\"Iressa\", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein\/ABCG2-mediated drug resistance","volume":"65","author":"Nakamura","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2025.118497_bb1045","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ejmech.2018.10.026","article-title":"Synthesis and biological evaluation of quinazoline derivatives \u2013 a SAR study of novel inhibitors of ABCG2","volume":"161","author":"Krapf","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb1050","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3390\/biom13020253","article-title":"Design, synthesis and biological evaluation of Quinazolinamine derivatives as breast Cancer resistance protein and P-glycoprotein inhibitors with improved metabolic stability","volume":"13","author":"Cai","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.bmc.2025.118497_bb1055","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1038\/sj.onc.1206948","article-title":"P-glycoprotein: from genomics to mechanism","volume":"22","author":"Ambudkar","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.bmc.2025.118497_bb1060","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.addr.2015.03.001","article-title":"Prediction of drug-ABC-transporter interaction--Recent advances and future challenges","volume":"86","author":"Montanari","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.bmc.2025.118497_bb1065","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/j.jacc.2013.02.058","article-title":"The P-glycoprotein transport system and cardiovascular drugs","volume":"61","author":"Wessler","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.bmc.2025.118497_bb1070","doi-asserted-by":"crossref","first-page":"7725","DOI":"10.1038\/s41467-023-43175-5","article-title":"Tamoxifen for the treatment of myeloproliferative neoplasms: a phase II clinical trial and exploratory analysis","volume":"14","author":"Fang","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2025.118497_bb1075","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.clpt.2004.09.001","article-title":"P-glycoprotein and surfactants: effect on intestinal talinolol absorption","volume":"77","author":"Bogman","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bmc.2025.118497_bb1080","doi-asserted-by":"crossref","first-page":"14895","DOI":"10.1021\/acs.jmedchem.1c01452","article-title":"Discovery of new 4-Indolyl Quinazoline derivatives as highly potent and orally bioavailable P-glycoprotein inhibitors","volume":"64","author":"Yuan","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb1085","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202200027","article-title":"Overcoming multidrug resistance (MDR): design, biological evaluation and molecular modelling studies of 2,4-substituted Quinazoline derivatives","volume":"17","author":"Braconi","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2025.118497_bb1090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116039","article-title":"Discovery of (quinazolin-6-yl)benzamide derivatives containing a 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline moiety as potent reversal agents against P-glycoprotein-mediated multidrug resistance","volume":"264","author":"Xue","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb1095","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1021\/acs.jmedchem.3c02140","article-title":"Discovery of five SOS2 fragment hits with binding modes determined by SOS2 X-ray Cocrystallography","volume":"67","author":"Smith","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb1100","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1073\/pnas.1812963116","article-title":"Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction","volume":"116","author":"Hillig","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmc.2025.118497_bb1105","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/1878-0261.13564","article-title":"SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma","volume":"18","author":"Theard","year":"2024","journal-title":"Mol Oncol"},{"key":"10.1016\/j.bmc.2025.118497_bb1110","doi-asserted-by":"crossref","first-page":"eaar8371","DOI":"10.1126\/scisignal.aar8371","article-title":"Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation","volume":"11","author":"Sheffels","year":"2018","journal-title":"Sci Signal"},{"key":"10.1016\/j.bmc.2025.118497_bb1115","doi-asserted-by":"crossref","unstructured":"Zak K.M., Waterson A.G., Geist L., et al. Discovery of small molecules that bind to Son of Sevenless 2 (SOS2). J Med Chem. 2025;68:2680-2693.","DOI":"10.1021\/acs.jmedchem.4c02007"},{"key":"10.1016\/j.bmc.2025.118497_bb1120","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s42004-025-01662-4","article-title":"Discovery of KRAS(G12D) selective degrader ASP3082","volume":"8","author":"Yoshinari","year":"2025","journal-title":"Commun Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb1125","first-page":"955","article-title":"Next batter up! Targeting cancers with KRAS-G12D mutations, trends","volume":"9","author":"Zeissig","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.bmc.2025.118497_bb1130","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","article-title":"Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor","volume":"28","author":"Hallin","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.bmc.2025.118497_bb1135","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.ccell.2024.06.001","article-title":"Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer","volume":"42","author":"Zhou","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bmc.2025.118497_bb1140","doi-asserted-by":"crossref","first-page":"eads0239","DOI":"10.1126\/science.ads0239","article-title":"A neomorphic protein interface catalyzes covalent inhibition of RAS(G12D) aspartic acid in tumors","volume":"389","author":"Weller","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.bmc.2025.118497_bb1145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118004","article-title":"The design and synthesis of selective and potent selenium-containing KRAS(G12D) inhibitors","volume":"298","author":"Zhou","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb1150","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2025.108889","article-title":"Recent advances in therapeutic targeting of the KRAS pathway in cancer","volume":"273","author":"Hitchen","year":"2025","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmc.2025.118497_bb1155","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13046-025-03369-9","article-title":"RASON promotes KRAS(G12C)-driven tumor progression and immune evasion in non-small cell lung cancer","volume":"44","author":"Wu","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.bmc.2025.118497_bb1160","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmc.2025.118497_bb1165","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116962","article-title":"Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents","volume":"71","author":"Li","year":"2022","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb1170","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.tcb.2010.02.002","article-title":"Evaluating smoothened as a G-protein-coupled receptor for hedgehog signalling","volume":"20","author":"Ayers","year":"2010","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.bmc.2025.118497_bb1175","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nature18934","article-title":"Structural basis of smoothened regulation by its extracellular domains","volume":"535","author":"Byrne","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2025.118497_bb1180","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41422-022-00622-0","article-title":"Cholesterylation of smoothened is a calcium-accelerated autoreaction involving an intramolecular ester intermediate","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res"},{"key":"10.1016\/j.bmc.2025.118497_bb1185","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41401-018-0019-5","article-title":"Novel-smoothened inhibitors for therapeutic targeting of na\u00efve and drug-resistant hedgehog pathway-driven cancers","volume":"40","author":"Li","year":"2018","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.bmc.2025.118497_bb1190","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1177\/00220345221100773","article-title":"New Ameloblastoma cell lines enable preclinical study of targeted therapies","volume":"101","author":"Nguyen","year":"2022","journal-title":"J Dent Res"},{"key":"10.1016\/j.bmc.2025.118497_bb1195","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1074\/jbc.RA119.010727","article-title":"Structure of an ancestral mammalian family 1B1 cytochrome P450 with increased thermostability","volume":"295","author":"Bart","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb1200","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1182\/blood-2008-03-145219","article-title":"CYP1B1 expression promotes the proangiogenic phenotype of endothelium through decreased intracellular oxidative stress and thrombospondin-2 expression","volume":"113","author":"Tang","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bmc.2025.118497_bb1205","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1158\/1078-0432.CCR-04-2111","article-title":"Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy","volume":"11","author":"Gribben","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2025.118497_bb1210","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/sj.bjc.6600719","article-title":"Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo","volume":"88","author":"Leong","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bmc.2025.118497_bb1215","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.biomaterials.2016.05.041","article-title":"Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer","volume":"101","author":"Brinkman","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.bmc.2025.118497_bb1220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118000","article-title":"Trans-Styrylquinazolinone CYP1B1 inhibitors as potential therapeutics in A549 cells","volume":"298","author":"Cai","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb1225","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1039\/C9CS00720B","article-title":"Advances in covalent kinase inhibitors","volume":"49","author":"Abdeldayem","year":"2020","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.bmc.2025.118497_bb1230","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.tips.2020.12.005","article-title":"Biased allosteric modulators: new Frontiers in GPCR drug discovery","volume":"42","author":"Slosky","year":"2021","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bmc.2025.118497_bb1235","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.bmc.2025.118497_bb1240","doi-asserted-by":"crossref","first-page":"100047","DOI":"10.1016\/j.pscia.2024.100047","article-title":"Targeting active RAS with molecular glue","volume":"2","author":"Su","year":"2024","journal-title":"Pharm Sci Adv"},{"key":"10.1016\/j.bmc.2025.118497_bb1245","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1007\/s11030-025-11111-y","article-title":"Molecular modeling aided design, synthesis and biological evaluation of quinazoline derivatives for the treatment of human cancer","volume":"29","author":"Liu","year":"2025","journal-title":"Mol Divers"},{"key":"10.1016\/j.bmc.2025.118497_bb1250","doi-asserted-by":"crossref","first-page":"116980","DOI":"10.1016\/j.ejmech.2024.116980","article-title":"Discovery of quinazoline-benzothiazole derivatives as novel potent protease-activated receptor 4 antagonists with improved pharmacokinetics and low bleeding liability","volume":"280","author":"Li","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118497_bb1255","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrd4333","article-title":"Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery","volume":"13","author":"Torchilin","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2025.118497_bb1260","doi-asserted-by":"crossref","first-page":"8362","DOI":"10.7150\/thno.39816","article-title":"Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy","volume":"9","author":"Garbuzenko","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.bmc.2025.118497_bb1265","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41419-024-06804-5","article-title":"Mitophagy-related regulated cell death: molecular mechanisms and disease implications","volume":"15","author":"Yang","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.bmc.2025.118497_bb1270","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/s41556-024-01429-4","article-title":"Mitochondria and cell death","volume":"26","author":"Glover","year":"2024","journal-title":"Nat Cell Biol"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625004389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625004389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:40:01Z","timestamp":1781253601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625004389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":254,"alternative-id":["S0968089625004389"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118497","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unveiling the power of quinazoline derivatives: a new frontier in targeted cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118497","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118497"}}